XML 79 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Intangible Assets [Line Items]      
Accumulated goodwill impairment losses $ 0    
Discount rate of acquired IPR&D 6.50% 8.00% 9.50%
In-process research and development impairment $ 0 $ 0 $ 800,000,000
Kite Pharma, Inc.      
Intangible Assets [Line Items]      
In-process research and development impairment     800,000,000
Cost of goods sold      
Intangible Assets [Line Items]      
Aggregate amortization expense related to finite-lived intangible assets $ 1,700,000,000 $ 1,200,000,000 $ 1,100,000,000